Obrigado pelo update. Não tinha reparado nesse aumento de capital. Em que data exacta é que as acções negociaram sem direitos? É que seria interessante ver se a queda do pico de $48 aconteceu apenas por ajuste devido ao aumento.
Bom dia Kin2010,
A única informação que consegui obter foi a seguinte:
On
November 12, 2013, we issued and sold 6,800,000 shares of our common stock in the IPO at a public offering price of $16.00 per share, for aggregate gross proceeds of $108.8 million.
On December 10, 2013, we issued and sold 1,020,000 shares of our common stock pursuant to the underwriters' full exercise of their option to purchase additional shares in the IPO at $16.00 per share for gross proceeds of $16.3 million. All of the shares issued and sold in the IPO were registered under the Securities Act pursuant to a Registration Statement on Form S-1 (File No. 333-191584), which was declared effective by the SEC on November 5, 2013, and a Registration Statement on Form S-1 (File No. 333-192110) filed pursuant to Ru
le 462(b) of the Securities Act. Merrill Lynch, Pierce, Fenner & Smith Incorporated and Leerink Swann LLC acted as joint-book-running m
anagers of the offering and as representatives of the underwriters. JMP Securities LLC and Oppenheimer & Co. Inc. acted as co-managers for the offering. The offering commenced on November 5, 2013 and terminated upon sale of all of the shares offered.
----------------------
In
July 2014, we completed a public offering of 2,844,334 shares of our common stock at a public offering price of $42.50 per share. We received net proceeds of approximately $112.8 million, after deducting underwriting discounts, commissions and expenses payable by us.
-----------------------
ETC
-----------------------
On January 6, 2015, Karyopharm Therapeutics Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) by and among the Company, certain stockholders of the Company named in Exhibit B to the Underwriting Agreement (the “Selling Stockholders”), and Merrill Lynch, Pierce, Fenner & Smith Incorporated and J.P. Morgan Securities LLC, as representatives of the several underwriters (collectively, the “Underwriters”), relating to an underwritten public offering of 3,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). Of the Shares,
2,950,000 are being sold by the Company and 50,000 are being sold by the Selling Stockholders. The offering price to the public is $33.00 per share, and the Underwriters have agreed to purchase the Shares from the Company and the Selling Stockholders pursuant to the Underwriting Agreement at a price of $31.02 per share. After underwriting discounts and commissions and estimated offering expenses, the Company expects to receive net proceeds from the offering of approximately $90.9 million.
------------------------
Onde eu vi o número de acções foi aqui
http://financials.morningstar.com/income-statement/is.html?t=KPTI .
É uma questão de ver que tipo de influencia tiveram estes aumentos de capital na cotação.
Parece que o último foi em Janeiro 6 2015 como está em cima indicado. Se olharmos para o gráfico, a última queda da cotação mais relevante iniciou-se em 5 de Janeiro, tendo quebrado o eventual suporte nos 29 dolares.
Em Julho de 2014 também ocorreu uma queda na cotação, o que coincide com outro dos aumentos de capital.
Abraço!
